Recombinant human VEGF Receptor 3 protein (ab95247)

Overview

Description

  • NatureRecombinant
  • SourceBaculovirus
  • Amino Acid Sequence
    • SpeciesHuman
    • Amino acids798 to 1298

Specifications

Our Abpromise guarantee covers the use of ab95247 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activitySpecific Activity: 17 pmol/min/µg. Assay conditions: VEGFR3 was incubated with a substrate (Tyr peptide 4 for 1h at RT in 1Xkinase buffer supplemented with ATP. Developer solution was added to reaction and reaction was stopped after 1h of incubation at RT.
  • Applications

    SDS-PAGE

    Functional Studies

  • Purity> 70 % SDS-PAGE.
    ab95247 is >70% pure as assessed by SDS PAGE.
  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on Dry Ice. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle.

    Preservative: None
    Constituents: 20% Glycerol, 0.05% Tween 20, 3mM DTT, 25mM Tris HCl, 138mM Sodium chloride, pH 8.0

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • EC 2.7.10.1
    • flt 4
    • FLT-4
    • FLT4
    • FLT41
    • Fms related tyrosine kinase 4
    • Fms-like tyrosine kinase 4
    • LMPH1A
    • PCL
    • Soluble VEGFR3 variant 1
    • Soluble VEGFR3 variant 2
    • Soluble VEGFR3 variant 3
    • Tyrosine protein kinase receptor FLT4
    • Tyrosine-protein kinase receptor FLT4
    • Vascular endothelial growth factor receptor 3
    • Vascular endothelial growth factor receptor 3 precursor
    • VEGF R3
    • VEGFR 3
    • VEGFR-3
    • VEGFR3
    • VGFR3_HUMAN
    see all
  • FunctionReceptor for VEGFC. Has a tyrosine-protein kinase activity.
  • Tissue specificityPlacenta, lung, heart, and kidney, does not seem to be expressed in pancreas and brain.
  • Involvement in diseaseDefects in FLT4 are the cause of lymphedema hereditary type 1A (LMPH1A) [MIM:153100]; also known as Nonne-Milroy lymphedema or Milroy disease. Hereditary lymphedema is a chronic disabling condition which results in swelling of the extremities due to altered lymphatic flow. Patients with lymphedema suffer from recurrent local infections and physical impairment.
    Note=Defects in FLT4 are found in juvenile hemangioma. Juvenile hemangiomas are the most common tumors of infancy, occurring as many as 10% of all births. These benign vascular lesions enlarge rapidly during the first year of life by hyperplasia of endothelial cells and attendant pericytes, and then spontaneously involute over a period of years, leaving loose fibrofatty tissue.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Cellular localizationMembrane.
  • Information by UniProt

Recombinant human VEGF Receptor 3 protein images

  • The specific activity of ab95247 was found to be 17 pmol/min/µg by carrying out functional studies. The assay conditions were; VEGFR3 was incubated with a substrate (Tyr peptide 4) for 1h at RT in 1Xkinase buffer supplemented with ATP. Developer solution was added to reaction and reaction was stopped after 1h of incubation at RT.
  • ab95247 was analysed by SDS-PAGE. Lane 1; ab95247 at 4µg. Lane 2; protein molecular weight markers. ab95247 has a predicted molecular weight of 82 kDa and is >70% pure as assessed by SDS-PAGE.

References for Recombinant human VEGF Receptor 3 protein (ab95247)

ab95247 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab95247.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"